Drug/indication: Ridaforolimus for sarcoma
Estimated timing: Before year's end.Recent stock performance: Closed Tuesday at $2.73, off its recent high of $4.25 reached in mid May. The phase III "SUCCEED" study is designed to detect a 33% improvement in median progression-free survival between "rida" and placebo in patients with soft-tissue or bone sarcoma who were previously treated, successfully, with chemotherapy. Full enrollment in the study of 650 patients was reached in December 2009 and independent study monitors completed their last interim check in May, recommending the study proceed to a final analysis. Ariad licensed worldwide commercial rights to rida to Merck (MRK). The two companies recently restructured the terms of the partnership.